Gables Capital Management Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 2.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 65,990 shares of the biopharmaceutical company’s stock after buying an additional 1,507 shares during the quarter. Pfizer comprises approximately 1.9% of Gables Capital Management Inc.’s portfolio, making the stock its 14th largest position. Gables Capital Management Inc.’s holdings in Pfizer were worth $2,383,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in PFE. W.G. Shaheen & Associates DBA Whitney & Co purchased a new stake in Pfizer in the first quarter valued at approximately $132,000. Braun Bostich & Associates Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $139,000. Clearwater Capital Advisors LLC purchased a new stake in Pfizer in the first quarter valued at approximately $156,000. Goodwin Daniel L purchased a new stake in Pfizer in the second quarter valued at approximately $171,000. Finally, Bristol John W & Co. Inc. NY purchased a new stake in Pfizer in the first quarter valued at approximately $186,000. 69.08% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PFE stock opened at $43.21 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. The firm has a market cap of $262.58 billion, a P/E ratio of 16.31, a PEG ratio of 2.22 and a beta of 0.88. Pfizer Inc. has a 12 month low of $33.20 and a 12 month high of $45.81.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to the consensus estimate of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The company’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.67 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 3 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.15%. Pfizer’s payout ratio is currently 51.32%.

A number of analysts have issued reports on PFE shares. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research report on Wednesday, October 17th. Morgan Stanley set a $45.00 target price on Pfizer and gave the company a “buy” rating in a research report on Thursday, September 13th. Barclays set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Friday, October 19th. BMO Capital Markets restated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a research note on Monday, August 27th. Finally, Credit Suisse Group set a $40.00 price target on shares of Pfizer and gave the stock a “hold” rating in a research note on Sunday, October 14th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.67.

In other news, major shareholder Pfizer Inc bought 55,556 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now owns 21,976,484 shares in the company, valued at approximately $395,576,712. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: What is the 52-week high/low?

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.